All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Over the past 20 years, the prognosis of Philadelphia chromosome-negative (Ph−) B-cell or T-cell acute lymphoblastic leukemia (ALL) has significantly improved with the introduction of intensive chemotherapy protocols and targeted therapies such as immunotoxins, T-cell bispecific engagers, and chimeric antigen receptor T-cell therapies. The use of allogeneic hematopoietic stem cell transplantation is widely debated in patients with Ph− ALL, as these patients can now be effectively treated without this highly toxic procedure.
Here, we present a debate by Chevallier.1 and Boissel.2 published in The Lancet Hematology on whether patients with Ph− ALL who reach measurable residual disease (MRD) negativity should receive allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Figure 1. Debate on whether allo-HSCT should be given to patients with Ph− ALL who reach MRD-negativity*
ALL, acute lymphoblastic leukemia; allo-HSCT, allogeneic hematopoietic stem cell transplantation; MRC, Medical Research Council; MRD, measurable residual disease; OS, overall survival; PCR, polymerase chain reaction; R/R, relapsed/refractory; WBC, white blood count.
*Adapted from Chevallier.1 and Boissel.2
Key learnings |
|
Your opinion matters
Subscribe to get the best content related to ALL delivered to your inbox